Intermittent Oral Versus Intravenous Alfacalcidol in Dialysis Patients
Patients with end-stage renal failure (ESRF) on maintenance dialysis, commonly develop secondary hyperparathyroidism and renal osteodystrophy (ROD). Alfacalcidol, taken orally or administered intravenously, is known to reverse these complications. In this study, 19 ESRF patients, who were on dialysi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2000-01-01
|
| Series: | Saudi Journal of Kidney Diseases and Transplantation |
| Subjects: | |
| Online Access: | http://www.sjkdt.org/article.asp?issn=1319-2442;year=2000;volume=11;issue=2;spage=174;epage=180;aulast=Mitwalli |